Report Highlights

UK Gastritis Treatment Market: Market Overview

The UK gastritis treatment market is structured around NHS-funded prescribing pathways, NICE clinical guidelines, and a generics-dominant pharmaceutical supply base. The market encompasses proton pump inhibitors (PPIs), H2 receptor antagonists, bismuth-containing compounds, antibiotics for H. pylori eradication, and antacids available both on prescription and over the counter. Public sector procurement through NHS England and the devolved health systems in Scotland, Wales, and Northern Ireland accounts for the majority of treatment spend, with private gastroenterology clinics representing a growing but still secondary channel. The NHS Long Term Plan's emphasis on primary care-led management of gastrointestinal conditions has reinforced the dominance of GP-prescribed PPI therapy as first-contact treatment.

Private sector participation has been shaped primarily by generic pharmaceutical manufacturers entering the market as branded PPI patents expired, compressing margins but broadening access. Takeda's Dexilant and AstraZeneca's legacy Nexium brand have ceded significant volume to generic esomeprazole and omeprazole produced by Dr. Reddy's Laboratories and Sandoz. Diagnostic infrastructure — including urea breath testing and gastroscopy — sits predominantly within NHS trusts, though Spire Healthcare and Nuffield Health operate private endoscopy suites that feed treatment pathways for H. pylori-positive patients. The market's overall trajectory is driven more by demographic ageing and NSAID-associated gastropathy in multi-morbid patients than by new molecular entities, marking it as a volume-stable but policy-sensitive market.

Policy-Driven Growth in UK Gastritis Treatment

NICE guideline NG238, published in 2023 and covering the management of dyspepsia in adults, is the single most consequential policy document shaping demand in this market. It mandates H. pylori testing prior to empirical PPI prescribing in uninvestigated dyspepsia, a requirement that directly increases urea breath test volumes and subsequent antibiotic eradication therapy demand across all NHS commissioning regions. NICE NG238 also recommends annual review of long-term PPI prescribing, which paradoxically sustains PPI volumes by formalising repeat prescription reviews rather than reducing them. The mechanism is clear: guideline-mandated testing generates confirmed diagnoses, and confirmed diagnoses generate billable treatment episodes — a cycle that is structurally embedded in NHS primary care workflows.

The UK Antimicrobial Resistance National Action Plan 2024–2029, coordinated by the UK Health Security Agency (UKHSA), is a second major policy driver. Its stewardship requirements are reshaping H. pylori eradication regimen selection away from clarithromycin-based triple therapy toward bismuth-based quadruple therapy incorporating bismuth subcitrate, metronidazole, tetracycline, and a PPI. UKHSA's Target HCAI and AMR programme allocates NHS England funding specifically for resistance surveillance in gastrointestinal pathogens, including H. pylori, creating a feedback loop that validates formulary changes. A third mechanism is the NHS Community Pharmacy Consultation Service, which now directs patients with dyspepsia symptoms to community pharmacies before GP referral, expanding OTC antacid and alginate consumption and growing that sub-segment independently of prescription volumes.

Regulatory Barriers and Compliance Costs

Market entry for new gastritis therapeutics in the UK is governed post-Brexit by the Medicines and Healthcare products Regulatory Agency (MHRA), which since January 2024 operates its own standalone licensing pathway separate from the European Medicines Agency. Companies seeking marketing authorisation for novel gastric acid suppressants or mucosal agents must now submit to the MHRA's national procedure, adding an estimated 12 to 18 months to approval timelines compared to the previous mutual recognition route. The MHRA's Innovation Office provides a fast-track dialogue mechanism, but this applies only to products meeting the Innovative Licensing and Access Pathway (ILAP) criteria, which standard-of-care gastritis drugs rarely qualify for, leaving most applicants on conventional assessment timelines and associated regulatory costs averaging £150,000 to £300,000 per application.

NHS England's Integrated Care Board (ICB) formulary governance presents a second-tier barrier. Even after MHRA approval, a product must be adopted onto local ICB formularies before NHS prescribing occurs at scale. This process involves health technology assessment submissions to the All Wales Medicines Strategy Group (AWMSG) and the Scottish Medicines Consortium (SMC) for devolved nations, each requiring separate submissions with economic modelling. NICE technology appraisals are mandatory for products with list prices that trigger cost-effectiveness thresholds, and the resulting delays — frequently 18 to 24 months post-authorisation — defer commercial revenues substantially. Local content rules do not formally apply, but NHS preferred supplier frameworks administered through NHS Supply Chain effectively favour established manufacturers with existing procurement relationships and proven supply reliability.

Policy-Created Opportunities in UK Gastritis Treatment

The NHS England Primary Care Transformation Programme creates a direct opportunity for companies supplying point-of-care H. pylori diagnostic kits. As GP surgeries transition to expanded clinical pharmacist teams under the Additional Roles Reimbursement Scheme (ARRS), in-practice urea breath testing capacity is increasing, and NHSE's 2024 Investment and Impact Fund includes quality indicators rewarding practices for completed H. pylori test-and-treat pathways. Manufacturers of rapid antigen stool tests — such as Biohit's HpStarFLA and Meridian Bioscience's ImmunoCard STAT! — are positioned to capture formulary listings through NHS Supply Chain tenders that will be issued in 2025 and 2026, valued collectively at an estimated £40 million over three years.

The second major opportunity lies in the Medicines Optimisation agenda coordinated by NHS Pharmacy teams. NHS England's publication of the Overprescribing Review in 2021 and its successor Deprescribing Network has created structured demand for proton pump inhibitor review services within ICBs. Paradoxically, this generates commercial opportunity for companies offering switching products — specifically potassium-competitive acid blockers (P-CABs) such as vonoprazan — which are positioned as superior alternatives in H. pylori eradication regimens where PPI efficacy is compromised by CYP2C19 polymorphism in a subset of patients. MHRA granted vonoprazan a positive opinion in 2024, and NHS commissioning interest is confirmed through the NHSE Accelerated Access Collaborative's watchlist designation, creating a credible route to rapid formulary adoption pending NICE cost-effectiveness confirmation.

Market at a Glance

Leading Market Participants

• AstraZeneca
• Takeda Pharmaceutical
• Pfizer
• Bayer AG
• Dr. Reddy's Laboratories
• Sandoz (Novartis)
• Teva Pharmaceutical Industries
• Biohit Oyj
• Phathom Pharmaceuticals
• Reckitt Benckiser

Regulatory and Policy Environment

The primary legislative framework governing gastritis treatment in the UK is the Human Medicines Regulations 2012 (SI 2012/1916), administered by the MHRA, which sets the legal basis for marketing authorisation, pharmacovigilance, and post-market surveillance of all prescription and OTC gastric medicines. Following Brexit, the MHRA's Great Britain (GB) authorisation system operates independently of EU processes, with Northern Ireland retaining access to EMA-approved products under the Windsor Framework's Annex 2 medicines provisions — creating a bifurcated regulatory environment that adds compliance complexity for manufacturers supplying across all four UK nations. The MHRA's Pharmacovigilance Framework, updated in 2023, requires enhanced periodic safety update reports for long-term PPI products given emerging evidence linking chronic omeprazole and lansoprazole use to hypomagnesaemia and Clostridioides difficile risk.

Compared to EU peers, the UK framework is notably more fragmented due to the devolved health system's separate formulary bodies. France's Haute Autorité de Santé and Germany's IQWiG both operate single national HTA processes, whereas UK manufacturers must navigate NICE, SMC, and AWMSG sequentially, adding 6 to 12 months and £50,000 to £100,000 in incremental submission costs. Upcoming regulatory changes expected before 2027 include the MHRA's International Recognition Procedure (IRP), which will allow products approved by reference agencies — including the FDA and EMA — to receive accelerated GB authorisation, reducing timelines by an estimated 30 to 40% and lowering the barrier for US-approved gastritis therapeutics such as vonoprazan fumarate (Voquezna) to enter NHS pathways.

Long-Term Policy Outlook for UK Gastritis Treatment

By 2030, NHS England's Elective Recovery Plan is expected to drive a measurable shift toward community-based gastroscopy and test-and-treat services, reducing the share of gastritis diagnoses made in hospital settings and increasing the volume managed within primary care and community pharmacy. This structural change will increase the commercial importance of near-patient diagnostic tools and reduce the leverage of hospital formulary committees over prescribing decisions. NICE is scheduled to review NG238 in 2026, and public consultation documents indicate that the updated guideline will extend H. pylori testing mandates to asymptomatic high-risk groups — including first-generation South Asian and East Asian migrants — a change that will expand the treatable population by an estimated 300,000 to 400,000 additional patients annually.

The Antimicrobial Resistance National Action Plan's 2029 target of a 15% reduction in inappropriate antibiotic prescribing will continue to reshape eradication therapy protocols, accelerating the transition to culture-guided and susceptibility-tested H. pylori regimens. This creates long-term demand for molecular diagnostic platforms capable of resistance profiling — a category where companies including Meridian Bioscience and Bruker are investing in NHS-compatible assay development. Simultaneously, the anticipated expansion of NHS Genomics Medicine Service infrastructure into gastrointestinal pathogen profiling by 2028 will enable pharmacogenomic-guided PPI prescribing that accounts for CYP2C19 status, potentially creating a defined premium segment for P-CABs within an otherwise generics-saturated market and sustaining above-average revenue growth through 2032.

Market Segmentation

By Drug Class

• Proton Pump Inhibitors (PPIs)
• H2 Receptor Antagonists
• Bismuth-Containing Compounds
• Antibiotics (H. pylori Eradication)
• Potassium-Competitive Acid Blockers (P-CABs)
• Antacids and Alginates

By Indication

• H. pylori-Associated Gastritis
• NSAID-Induced Gastritis
• Autoimmune Gastritis
• Alcoholic and Stress-Related Gastritis
• Chronic Atrophic Gastritis

By Distribution Channel

• NHS Hospital Pharmacy
• NHS Community Pharmacy
• Private Hospital and Clinic Pharmacy
• Over-the-Counter Retail
• Online Pharmacy

By End User

• NHS Primary Care (GP Practices)
• NHS Secondary Care (Hospital Trusts)
• Private Gastroenterology Clinics
• Community Pharmacies
• Integrated Care Boards

Frequently Asked Questions

Q1. Which NICE guideline governs H. pylori testing and treatment in the UK, and what are its key prescribing requirements? ▼

NICE guideline NG238 (2023) mandates H. pylori testing before empirical PPI prescribing in uninvestigated dyspepsia in adults. It also requires annual review of long-term PPI prescriptions across all NHS primary care settings.

Q2. How does the MHRA's post-Brexit regulatory pathway affect market entry timelines for new gastritis drugs? ▼

The MHRA's standalone Great Britain authorisation process adds an estimated 12 to 18 months compared to the former EMA mutual recognition route. The upcoming International Recognition Procedure is expected to reduce these timelines by 30 to 40% from 2027 onward.

Q3. What is the compliance requirement for NHS formulary listing, and which bodies must manufacturers engage? ▼

Manufacturers must secure listings from NICE for England, the Scottish Medicines Consortium for Scotland, and the All Wales Medicines Strategy Group for Wales — three separate HTA submissions each requiring independent economic modelling. This process routinely takes 18 to 24 months post-MHRA authorisation.

Q4. How does the UK Antimicrobial Resistance National Action Plan 2024–2029 affect gastritis treatment protocols? ▼

The plan, coordinated by UKHSA, steers H. pylori eradication away from clarithromycin-based triple therapy due to resistance rates exceeding 20% in major urban centres. Bismuth-based quadruple therapy is being elevated to preferred first-line status in updated NHS antimicrobial formulary guidance.

Q5. What regulatory status does vonoprazan hold in the UK, and what is its pathway to NHS prescribing? ▼

The MHRA granted vonoprazan a positive opinion in 2024, and it has received watchlist designation from the NHS England Accelerated Access Collaborative. Full NHS prescribing access depends on a pending NICE cost-effectiveness appraisal expected to conclude by 2026.